Published in The Lancet Neurology, a clinical evaluation reveals that the repurposed hypertension drug guanabenz slows or halts disease progression in children diagnosed with vanishing white matter (VWM), a fatal genetic brain disorder. Led by the Emma Children’s Hospital at Amsterdam UMC, the international study tracked 33 pediatric patients over four years, demonstrating clinical stabilization.
Vanishing white matter is a severe leukodystrophy—a genetic condition that progressively destroys the brain’s white matter, which consists of nerve fibers connecting various brain regions. Typically manifesting in early childhood between the ages of one and six, the disease robs patients of acquired motor and cognitive skills. Ordinary physical stressors like fevers or viral infections can trigger catastrophic, rapid declines, and most affected children do not survive past age six. Historically, clinicians could only offer palliative care, as no disease-modifying therapies existed to alter this fatal trajectory.
In Plain English: The Clinical Takeaway
- What was found: An old blood pressure medication called guanabenz successfully slows down the destruction of brain tissue in children with vanishing white matter.
- Real-world impact: Treated children stayed out of wheelchairs longer and showed zero deaths during the four-year study period, contrasting with mortality and rapid decline in untreated historical control groups.
- Current availability: The drug is not yet approved by the European Medicines Agency (EMA) for this specific indication and remains accessible strictly within clinical trial frameworks while regulatory filings are prepared.
Unlocking the Mechanism: How Guanabenz Targets Cellular Stress
The core pathology of vanishing white matter stems from a chronic, dysregulated integrated stress response (ISR) within glial cells, particularly astrocytes and oligodendrocytes. In healthy individuals, cells activate a temporary stress response to combat environmental pressures like viral pathogens or high fevers. In VWM patients carrying mutations in eukaryotic translation initiation factor 2B (eIF2B) genes, this cellular alarm system is permanently locked in the “on” position, even in the complete absence of external triggers.
This persistent cellular stress response starves cells of necessary protein synthesis, leading directly to apoptosis (programmed cell death) of myelin-producing cells and the characteristic spongy degeneration of white matter. According to investigations published in medical literature, guanabenz acts on the alpha-2 adrenergic receptor and selectively inhibits protein phosphatase 1 regulatory subunit 15A (known as PPP1R15A or GADD34). By blocking this pathway, guanabenz dampens the overactive stress response, protecting vulnerable neural tissue from further degenerative damage.
Clinical Trial Design and Patient Outcomes
To evaluate the efficacy of guanabenz, researchers administered the drug to 33 pediatric patients across multiple international sites for a duration of four years.
The findings demonstrated striking clinical differences between the two cohorts. Children receiving guanabenz experienced delayed or reduced progression toward wheelchair dependency. Furthermore, serial neuroimaging via MRI scans revealed arrested or significantly decelerated deterioration of cerebral white matter. Most notably, zero fatalities occurred among the 33 treated children during the four-year observation window, whereas five deaths were recorded within the 66-patient untreated comparison group.
Subgroup analyses revealed that therapeutic efficacy was most pronounced in children whose symptom onset occurred at or after three years of age. Regarding safety profiles, adverse events such as transient somnolence (extreme sleepiness), hypotension (low blood pressure), constipation, and mild hallucinations manifested predominantly during the initial months of administration. These side effects proved manageable, subsiding significantly by months four to six, and zero participants discontinued the trial due to adverse pharmacological reactions.
| Metric | Guanabenz Cohort (n=33) | Untreated Control Group (n=66) |
|---|---|---|
| Study Duration | 4 Years | Matched historical registry |
| Mortality Rate During Study | None (0 deaths) | 5 deaths out of 66 patients |
| Motor Function Impact | Delayed/reduced progression to wheelchair use | Rapid loss of independent mobility |
| White Matter MRI Changes | Stabilized or slowed degeneration | Progressive, rapid structural loss |
| Primary Adverse Events | Transient somnolence, low blood pressure, constipation | N/A (Standard disease progression) |
Research Leadership and Financial Transparency
The clinical trial was spearheaded by academic neurologists at the Emma Children’s Hospital, part of Amsterdam UMC. Professor Marjo van der Knaap, a recognized authority in pediatric neurology who led the research, noted the gravity of the milestone. Amsterdam UMC commissioned the specialized compounding of guanabenz specifically for trial participants, as commercial pharmaceutical manufacturers had previously discontinued mass production due to the availability of newer antihypertensive medications.
This public and philanthropic investment bridged the financial gap necessary to transition laboratory discoveries concerning cellular stress pathways into a structured human clinical trial.
Regulatory Horizons and Patient Access in Europe and Beyond
Despite these promising outcomes, medical experts emphasize that guanabenz does not currently constitute a permanent cure. Discontinuing the pharmaceutical intervention halts its protective benefits, meaning the underlying degenerative process resumes if the medication is withdrawn.
Consequently, clinical access is currently restricted to formalized study protocols. However, institutional leaders at Amsterdam UMC have initiated preliminary engagements with the EMA to secure regulatory approval, aiming to transition the therapy into routine clinical practice for affected families outside of trials.
Contraindications & When to Consult a Doctor
Future Outlook
Researchers are designing follow-up clinical phases to evaluate optimized dosing regimens and extended longitudinal tracking. While regulatory hurdles remain before widespread prescription access is secured, these findings provide a scientific foundation for treating a condition previously deemed entirely refractory to medicine.
References
- Van der Knaap, M. S., et al. (2026). “Guanabenz therapy in vanishing white matter disease.” The Lancet Neurology.
- Amsterdam UMC. (2026). “Geneesmiddel remt zeldzame hersenziekte bij kinderen.” Retrieved from amsterdamumc.org.
- Hersenstichting. (2026). “Bloeddrukmedicijn remt hersenziekte bij kinderen.” Retrieved from hersenstichting.nl.
